Anti-inflammatory effect of collagen tripeptide in atopic dermatitis

What Was Tested

The paper reports a study of Tripeptide-29 (Collagen Tripeptide), published as a randomized controlled trial.

To examine the effect of CTP on inflammation in AD.

To evaluate the functional effect of CTP, a migration assay was performed using the supernatants of cultured keratinocytes treated with CTP.

Why It Was Studied

Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease in which type 2 allergic inflammation plays an important role.

Collagen tripeptide (CTP) is a functional collagen fraction with a high content of Gly-X-Y tripeptides.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Levels of inflammatory cytokines and chemokines, such as thymus- and activation-regulated chemokine (TARC), macrophage-derived chemokine, and thymic stromal lymphopoietin (TSLP), were examined in human keratinocytes supplemented with or without CTP under AD-like inflammation.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Because people in this Tripeptide-29 (Collagen Tripeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Tripeptide-29 (Collagen Tripeptide), so expectations could not easily colour the readings.

The signaling pathway for CTP inhibitory activity was also determined.

The eruption area, severity scoring of atopic dermatitis (SCORAD), skin hydration, transepidermal water loss (TEWL), and itching score were evaluated.

The levels of TARC, serum IgE, lactate dehydrogenase, and eosinophil counts at week 12 were also compared with those at the start of administration.

What Was Measured

Topics PubMed links to this paper include Anti-Inflammatory Agents, Cell Movement, Cells, Cultured, Chemokine CCL17, Collagen Type I, Cytokines and Dermatitis, Atopic.

Author keywords: Atopic dermatitis, Collagen tripeptide, Thymic stromal lymphopoietin and Thymus and activation-regulated chemokine.

What This Means in Plain Language

The paper is a randomized and double-blind study of Tripeptide-29 (Collagen Tripeptide).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Journal of dermatological science), a journal based in Netherlands.

More context: the Tripeptide-29 (Collagen Tripeptide) compound page, all human trials.